TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: percentage of users that achieve consistency of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety (number of users reporting device/treatment-related adverse events)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Sleep Onset Latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Speech disyllabic recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Macular thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney allograft survival
Endpoint domain: Mortality/survival
Primary endpoint: Moderate-to-vigorous activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Horizontal jump test (meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical jumps tests (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 40-yard sprint test (sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower extremity functional scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Star excursion balance test (cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Continuity of the capsulorhexis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: N400
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: P600
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delayed Recognition Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of botulinum toxin effect on eyebrow excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of botulinum toxin effect on forehead rhytids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response time from baseline to post-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response time from post-test to follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in response time from baseline to follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of scar improvement evaluated by investigators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Efficacy of scar improvement evaluated by patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Itch assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of anti-protein S antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of Treatment-Related Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Most recent blood pressure measurement values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: The proportion of patients prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RA)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: The proportion of patients prescribed cardiovascular disease (CVD) medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective craving
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Second Primary Malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: The worse pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Spontaneous Bowel Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: SSE (Surgical Site Infection)
Endpoint domain: Adverse events/effects
Primary endpoint: Immediate postoperative performances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in appearance in the treated area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients receiving bystander resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Robustness of the PPG-signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of corneal staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount and activity of AK2 in colorectal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount and activity of CKM in colorectal tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount and activity of AK2 in peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Amount and activity of CKM in peripheral blood mononuclear cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Presence of intracerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: ≥35% reduction in spleen volume (SVR35)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neutralizing antibody titer change 14 days after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutralizing antibody titer change 28 days post vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Systolic blood pressure measurements (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Orthostatic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Syncope free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in PCL-5 score over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Success rate of first attempt of endotracheal intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effectiveness of enteral-based resuscitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient treatment attendance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in ectopy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recovery after intravenous iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Finger reaction test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper extremity reaction test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Auditory Reaction Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants receiving cervical cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inattentive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major cardiac adverse events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Computed tomography vessel opacification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and clinical impact of pathological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoglycemic events 12 hours after completion of exercise challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glycemic variability during exercise challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to completion of distance bike challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sanfilippo Behavior Rating Scale (SBRS) - mood/anger/aggression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: RAI uptake pattern and kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HRV immediately post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HRV at 7 min post-intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain estimation during rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain estimation during activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Children Screen Positive for Delays Using the Ages and Stages Questionnaire (ASQ 3)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Patient Health Questionnaire (PHQ 9) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Protective Factors Survey Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Wheelchair User's Shoulder Pain Index (WUSPI) change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fracture and trauma details
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Visual assessment of the wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pinch fat of dog ears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual Activity questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Presence or absence of thirst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: modified Rankin Scale score (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fetal systolic and diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Clostridium difficile associated diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative six-minute walking distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to anuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: residual renal function (RRF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in the renal cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnosis rates of low ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of score on the lingual myofunctional analytical evaluation scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and Severity of Treatment-Emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Changes from baseline in CCL5 gene expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in CXCR3 gene expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose for expansion (RDE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with atrial fibrillation (AF) related hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients with atrial fibrillation (AF) related ED visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of patients with clinically significant atrial fibrillation post ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of treatment responders without chemotherapy modification due to thrombocytopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wisconsin Card Sorting Task perseverance score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Emotional Arousal task rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opioid progressive ratio breakpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical attachment gain (CAG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in gambling craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in gambling severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility as assessed by The Feasibility of Intervention Measure (FIM) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knowledge of the living will
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceptions of Health Outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with HBV DNA <20 IU/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in Estimated Glomerular Filtration Rate by the Cockcroft-Gault Formula (eGFR-CG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Systolic and Diastolic Blood Pressure Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morphological carotid plaque stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Carotid plaque regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of participants with adverse events (AEs)/treatment-emergent adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of potentially Clinical laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Tampa Kinesiophobia Scale (TKS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: BeCure Balance Evaluation System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspirin reaction units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative Heart Failure hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of MPT0B640
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient experience during percutaneous organ biopsy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Operator experience during percutaneous organ biopsy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lumbar Ranges of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Disability Level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Anti-Drug Antibodies (ADA)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Plasma Inorganic Pyrophosphate (PPi) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Effectiveness of Teddy Bear Injury Clinic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Engraftment of SER-155
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with DVT and/or PTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 14-day hospital-free days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of population screened for study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concentration of Zoledronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of Zoledronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach maximum concentration of Zoledronic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β2-microglobulin (β2-MG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: indoxyl sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: λ-free light chain (λFLC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-oral examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal nerve fiber layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central retinal artery and vein calibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Resource Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total fentanyl consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pediatric Rating of Chronic Illness Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in pain score on visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Petco2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilation leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Local Reactions Within 7 Days After Last Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Systemic Events Within 7 Days After Last Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events (AEs) From Last Vaccination to 1 Month After Last Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Serious Adverse Events (SAEs) From Last Vaccination to 1 Month After Last Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Dim Light Melatonin Onset (DLMO) Phase Shift Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Mean Change From Baseline in TSQM Overall Satisfaction Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC[0-t]) for Ibuprofen in Fasted Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Time Curve (AUC[0-inf]) for Ibuprofen in Fasted Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Plasma Concentration (Cmax) for Ibuprofen in Fasted Conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of phantom limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of phantom limb sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the screening program
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom Improvement Rate at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Main Symptom Resolution Rate at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of placenta previa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Weekly changes of Five Facet Mindfulness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Assessment of sings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disaster literacy scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Disaster preparedness scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disaster Resilience Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bayley cognitive scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayley language scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gesture production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuromuscular transmission nerve monitoring concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute toxicity outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Perceived Stress Scale-10
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in absorbing product leakage rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in headache days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: CMV Viremia-Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in mGFR percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes